$32.18
+0.61
(+1.93%)▲
Revenue is down for the last 2 quarters, 133.57M → 106.07M (in $), with an average decrease of 20.6% per quarter
Netprofit is up for the last 2 quarters, 37.70M → 40.50M (in $), with an average increase of 6.9% per quarter
In the last 1 year, Boston Scientific Corp. has given 26.6% return, outperforming this stock by 5.5%
1.55%
Downside
Day's Volatility :2.13%
Upside
0.59%
34.12%
Downside
52 Weeks Volatility :49.33%
Upside
23.09%
Period | Inmode Ltd | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -6.59% | 0.7% | -7.0% |
6 Months | -14.28% | -7.9% | -6.5% |
1 Year | 21.11% | -2.0% | -6.8% |
3 Years | 107.35% | 25.4% | 24.7% |
Market Capitalization | 2.6B |
Book Value | $7.25 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | 1.99 |
PE Ratio | 15.86 |
PEG Ratio | 2.9 |
Wall Street Target Price | 47.0 |
Profit Margin | 36.05% |
Operating Margin TTM | 42.97% |
Return On Assets TTM | 22.47% |
Return On Equity TTM | 34.0% |
Revenue TTM | 474.4M |
Revenue Per Share TTM | 5.75 |
Quarterly Revenue Growth YOY | 23.5% |
Gross Profit TTM | 380.8M |
EBITDA | 204.6M |
Diluted Eps TTM | 1.99 |
Quarterly Earnings Growth YOY | 0.31 |
EPS Estimate Current Year | 2.63 |
EPS Estimate Next Year | 2.99 |
EPS Estimate Current Quarter | 0.47 |
EPS Estimate Next Quarter | 0.65 |
What analysts predicted
Upside of 46.05%
FY17 | Y/Y Change | |
---|---|---|
Revenue | 53.5M | ↑ 131.59% |
Net Income | 8.8M | ↑ 2524.7% |
Net Profit Margin | 16.5% | ↑ 15.04% |
FY18 | Y/Y Change | |
---|---|---|
Revenue | 100.2M | ↑ 87.37% |
Net Income | 22.4M | ↑ 153.67% |
Net Profit Margin | 22.33% | ↑ 5.83% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 156.4M | ↑ 56.11% |
Net Income | 61.1M | ↑ 173.32% |
Net Profit Margin | 39.11% | ↑ 16.78% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 206.1M | ↑ 31.81% |
Net Income | 75.0M | ↑ 22.71% |
Net Profit Margin | 36.4% | ↓ 2.71% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 357.6M | ↑ 73.49% |
Net Income | 165.0M | ↑ 119.87% |
Net Profit Margin | 46.14% | ↑ 9.74% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 454.3M | ↑ 27.05% |
Net Income | 161.5M | ↓ 2.09% |
Net Profit Margin | 35.56% | ↓ 10.58% |
Q4 FY21 | Q/Q Change | |
---|---|---|
Revenue | 110.5M | ↑ 17.38% |
Net Income | 52.7M | ↑ 17.82% |
Net Profit Margin | 47.66% | ↑ 0.18% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Revenue | 85.9M | ↓ 22.27% |
Net Income | 31.0M | ↓ 41.21% |
Net Profit Margin | 36.05% | ↓ 11.61% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Revenue | 113.5M | ↑ 32.15% |
Net Income | 44.0M | ↑ 42.21% |
Net Profit Margin | 38.79% | ↑ 2.74% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 121.2M | ↑ 6.77% |
Net Income | 48.8M | ↑ 10.76% |
Net Profit Margin | 40.24% | ↑ 1.45% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 133.6M | ↑ 10.18% |
Net Income | 37.7M | ↓ 22.71% |
Net Profit Margin | 28.23% | ↓ 12.01% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 106.1M | ↓ 20.59% |
Net Income | 40.5M | ↑ 7.42% |
Net Profit Margin | 38.19% | ↑ 9.96% |
FY17 | Y/Y Change | |
---|---|---|
Total Assets | 39.4M | ↑ 139.22% |
Total Liabilities | 20.0M | ↑ 170.71% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 81.1M | ↑ 105.51% |
Total Liabilities | 36.4M | ↑ 82.0% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 218.4M | ↑ 169.42% |
Total Liabilities | 38.6M | ↑ 6.05% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 295.8M | ↑ 35.43% |
Total Liabilities | 40.3M | ↑ 4.42% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 478.5M | ↑ 61.8% |
Total Liabilities | 62.7M | ↑ 55.73% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 644.4M | ↑ 34.66% |
Total Liabilities | 89.8M | ↑ 43.12% |
Q4 FY21 | Q/Q Change | |
---|---|---|
Total Assets | 478.5M | ↑ 6.9% |
Total Liabilities | 62.7M | ↓ 1.4% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 464.5M | ↓ 2.94% |
Total Liabilities | 61.1M | ↓ 2.54% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 523.2M | ↑ 12.65% |
Total Liabilities | 70.4M | ↑ 15.12% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 579.0M | ↑ 10.66% |
Total Liabilities | 70.7M | ↑ 0.41% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 644.4M | ↑ 11.3% |
Total Liabilities | 89.8M | ↑ 27.04% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 669.6M | ↑ 3.91% |
Total Liabilities | 66.6M | ↓ 25.79% |
FY17 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 14.6M | ↑ 387.62% |
Investing Cash Flow | -5.7M | ↑ 1234.27% |
Financing Cash Flow | 1.8M | ↑ 3267.92% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 36.9M | ↑ 152.49% |
Investing Cash Flow | -29.7M | ↑ 423.21% |
Financing Cash Flow | 186.0K | ↓ 89.58% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 62.2M | ↑ 68.64% |
Investing Cash Flow | -112.5M | ↑ 278.13% |
Financing Cash Flow | 70.2M | ↑ 37627.42% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 79.2M | ↑ 27.36% |
Investing Cash Flow | -43.3M | ↓ 61.49% |
Financing Cash Flow | -12.4M | ↓ 117.73% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 174.9M | ↑ 120.74% |
Investing Cash Flow | -160.1M | ↑ 269.72% |
Financing Cash Flow | -15.0M | ↑ 20.74% |
Q4 FY21 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 52.9M | ↑ 4.79% |
Investing Cash Flow | -30.8M | ↓ 36.01% |
Financing Cash Flow | -22.9M | ↓ 540.46% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 31.9M | ↓ 39.78% |
Investing Cash Flow | -2.4M | ↓ 92.29% |
Financing Cash Flow | -42.5M | ↑ 85.45% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 47.0M | ↑ 47.49% |
Investing Cash Flow | -2.4M | ↑ 0.0% |
Financing Cash Flow | 204.0K | ↓ 100.48% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 45.6M | ↓ 2.96% |
Investing Cash Flow | -56.1M | ↑ 2264.49% |
Financing Cash Flow | 550.0K | ↑ 169.61% |
Sell
Neutral
Buy
Inmode Ltd is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Inmode Ltd | -4.88% | -14.28% | 21.11% | 107.35% | 374.28% |
![]() Stryker Corporation | -5.21% | 14.59% | 18.85% | 40.42% | 57.95% |
![]() Boston Scientific Corp. | -2.65% | 10.52% | 26.63% | 37.19% | 68.3% |
![]() Edwards Lifesciences Corp. | -2.94% | 11.34% | -15.79% | 13.9% | 79.08% |
![]() Abbott Laboratories | -7.78% | -4.88% | -12.5% | 11.01% | 63.15% |
![]() Medtronic PLC | -8.29% | 3.93% | -15.99% | -14.91% | -5.45% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Inmode Ltd | 15.86 | 15.86 | 2.9 | 2.63 | 0.34 | 0.22 | 0.0 | 7.25 |
![]() Stryker Corporation | 40.11 | 40.11 | 2.85 | 10.16 | 0.16 | 0.06 | 0.01 | 44.51 |
![]() Boston Scientific Corp. | 41.35 | 41.35 | 2.53 | 1.95 | 4.89 | 0.04 | 0.0 | 12.42 |
![]() Edwards Lifesciences Corp. | 35.24 | 35.24 | 3.07 | 2.55 | 0.25 | 0.13 | 0.0 | 9.87 |
![]() Abbott Laboratories | 24.71 | 24.71 | 18.76 | 4.4 | 16.03 | 0.06 | 0.02 | 21.28 |
![]() Medtronic PLC | 17.98 | 17.98 | 3.04 | 5.28 | 7.81 | 0.04 | 0.03 | 38.69 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Inmode Ltd | Buy | $2.6B | 374.28% | 15.86 | 36.05% |
![]() Stryker Corporation | Buy | $104.6B | 57.95% | 40.11 | 13.86% |
![]() Boston Scientific Corp. | Buy | $72.6B | 68.3% | 41.35 | 6.92% |
![]() Edwards Lifesciences Corp. | Buy | $51.1B | 79.08% | 35.24 | 27.07% |
![]() Abbott Laboratories | Buy | $176.9B | 63.15% | 24.71 | 13.98% |
![]() Medtronic PLC | Buy | $109.8B | -5.45% | 17.98 | 12.03% |
Acadian Asset Management LLC
Renaissance Technologies Corp
Millennium Management LLC
BlackRock Inc
American Century Companies Inc
William Blair Investment Management, LLC
InMode is a leading global provider of innovative medical technologies. InMode develops, manufactures, and markets devices harnessing novel radiofrequency ('RF') technology. InMode strives to enable new emerging surgical procedures as well as improve existing treatments. InMode has leveraged its medically accepted minimally-invasive RF technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology.
Organization | Inmode Ltd |
Employees | 480 |
CEO | Mr. Yair Malca |
Industry | Health Technology |
iShares MSCI Min Vol Global ETF
$96.84
+0.5%
Enlight Renewable Energy Ltd
$18.38
-0.65%
Brazil Capped ETF MSCI iShares
$29.72
+3.12%
CACI International Inc
$300.96
+0.58%
IAC Inc
$55.58
-0.47%
Chart Industries Inc.
$111.47
+1.59%
Affirm Holdings Inc
$14.58
-1.88%
BJ's Wholesale Club Holdings Inc
$62.18
-0.75%
SM Energy Company
$26.84
+2.09%